The clinical implications of using Bi(III)-bound NDM-1 as an antibiotic target could involve potential new treatment options for bacterial infections, particularly those caused by multidrug-resistant bacteria. This approach may offer a novel strategy to combat antibiotic resistance and improve patient outcomes in the future.